Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma
Executive Summary
Intrahepatic cholangiocarcinoma (ICC) is a primary liver cancer with a rising global incidence, particularly in East and Southeast Asia. The Liver Cancer Study Group of Japan (LCSGJ) has established the first version of evidence-based clinical practice guidelines to address the diagnosis, staging, and treatment of this disease.
The core findings of these guidelines emphasize a multidisciplinary approach:
Etiology: Risk factors are diverse, ranging from viral hepatitis (B and C) and cirrhosis to occupational chemical exposure (1,2-dichloropropane) and liver flukes.
Staging: Japan utilizes specific criteria (6th edition LCSGJ) that differ from Western (UICC) standards, primarily using a 2-cm tumor size cutoff and the inclusion of major biliary invasion as a prognostic determinant.
Diagnosis: Diagnosis relies on tumor markers (CA19-9 and CEA) and advanced imaging (Contrast-enhanced CT, EOB-MRI, and FDG-PET). Biopsy is primarily reserved for unresectable cases to guide drug selection.
Treatment: Surgical resection remains the only curative intent for resectable ICC, specifically for solitary tumors without lymph node metastasis (LNM). For unresectable cases, the standard of care has shifted toward triplet chemotherapy (Gemcitabine + Cisplatin + S-1). Emerging molecular targeted therapies (FGFR2, NTRK) offer new avenues for precision medicine.
Radiotherapy: Local control can be sought via stereotactic or particle radiotherapy for unresectable cases without extrahepatic metastasis.
1. Epidemiology and Etiology
1.1 Global and Regional Trends
The incidence of ICC is increasing worldwide. While Southeast Asia—specifically Northeast Thailand—reports the highest incidence (85 per 100,000 in men), Western countries and Japan have also seen steady rises. In Japan, ICC accounts for approximately 4.77% of all primary liver cancers.
1.2 Risk Factor Classification
The development of ICC is associated with persistent inflammation of the biliary tract and various liver-damaging agents.
2. Pathology and Staging
2.1 Staging Discrepancies: Japan vs. West
The LCSGJ 6th Edition staging differs significantly from the UICC 8th Edition. These differences are based on Japanese multivariate analyses of surgically resected cases.
Size Cutoff: Japan uses a 2-cm cutoff for T1, as patients with tumors ≤2 cm without LNM or vascular invasion show a 100% 5-year survival rate. The UICC uses a 5-cm cutoff.
Biliary Invasion: The Japanese system includes "major biliary invasion" (invasion of first-order branches or the common hepatic duct) as a T-stage factor, recognizing its severe prognostic impact.
Serosal Invasion: Included in UICC staging but omitted in Japanese T-staging as it was not found to be an independent prognostic factor in Japanese cohorts.
2.2 Precancerous and Early Lesions
Three primary precursor lesions are identified:
Biliary Intraepithelial Neoplasia (BilIN): Microscopic flat or micropapillary lesions.
Intraductal Papillary Neoplasm of Bile Duct (IPNB): Macroscopic papillary lesions often accompanied by mucus hypersecretion.
Mucinous Cystic Neoplasm (MCN): Cystic lesions with characteristic ovarian-like stroma, occurring predominantly in women.
3. Diagnostic Modalities
3.1 Screening and Blood Tests
No universal screening program exists; however, high-risk patients should undergo regular screening via US and tumor markers.
Markers: CA19-9 and CEA are strongly recommended. Elevated bilirubin and ALP may suggest malignant biliary stenosis.
Occupational Screening: Workers exposed to 1,2-dichloropropane are entitled to biannual checkups in Japan, including γ-GTP and CA19-9 measurements.
3.2 Imaging Modalities
US/CT/MRI: Mass-forming ICC typically presents as a hypointense mass on CT with ring-like early enhancement and delayed central enhancement due to fibrous stroma.
EOB-MRI: Highly effective for differentiating ICC from hepatocellular carcinoma (HCC). ICC typically appears hypointense in the hepatocellular phase.
FDG-PET: Useful for detecting mass-forming ICC ≥1 cm (sensitivity ~100%) and identifying occult lymph node or distant metastasis.
3.3 Tumor Biopsy
Biopsy is not recommended for resectable cases due to the risk of complications (0.5%, mainly bleeding) and potential peritoneal dissemination (2.7% in HCC studies). It is reserved for unresectable cases where histological confirmation is required to select appropriate drug therapies.
4. Treatment Framework
4.1 Surgical Resection (Curative Intent)
Surgery is the mainstay for patients with Child-Pugh class A or B liver function.
Best Indications: Solitary tumors without LNM, regardless of size.
Surgical Margins: The goal is R0 resection (negative margins).
Lymph Node Dissection: While 15% of patients have LNM at diagnosis, the therapeutic benefit of prophylactic dissection remains unclear. It is, however, recommended for accurate staging and informing adjuvant therapy.
4.2 Drug Therapy for Unresectable ICC
For patients with distant metastasis or extensive LNM combined with multiple tumors, systemic chemotherapy is the first-line choice.
Targeted and Second-line Therapies:
Pemigatinib: Approved for BTC with FGFR2 fusions/rearrangements (detected in 5.3%–13.6% of ICC).
Entrectinib/Larotrectinib: For NTRK fusion-positive solid tumors.
Pembrolizumab: For MSI-High tumors that have progressed after prior chemotherapy.
4.3 Radiotherapy and Ablation
Ablation (RFA): Considered for patients ineligible for surgery/chemo due to comorbidities or poor hepatic reserve, especially for tumors <3 cm.
Stereotactic Radiotherapy: Recommended for unresectable tumors ≤5 cm without metastasis.
Particle Radiotherapy: A promising option for large unresectable tumors, showing favorable local control with low serious toxicity.
5. Clinical Differentiation: Hilar Region
A critical clinical challenge is distinguishing between hilar cholangiocarcinoma and ICC involving the hepatic hilum. While they often share similar clinical management, pathological differentiation is possible through:
Elastica van Gieson staining: Identifying if the tumor is located outside the elastic fibers of the hilar region (indicating ICC) or within (indicating hilar cholangiocarcinoma).
Genetic Profiling: ICC-specific mutations (FGFR2 fusions, IDH1/2) versus ECC-specific mutations (PRKACA/B fusions) can aid in definitive diagnosis.
